[Abciximab in the treatment of acute coronary syndromes by angioplasty and stents].
Stents are indicated in the prevention and treatment of coronary occlusion and restenosis following percutaneous transluminal coronary angioplasty. ReoPro (abciximab) is a chimeric monoclonal antibody interfering with the IIb-IIIa glycoprotein platelet receptor. Its efficacy in preventing ischaemic events after coronary angioplasty was evaluated in the EPIC, EPILOG and CAPTURE studies. In these studies, 525 (9.6 per cent) patients were treated with coronary angioplasty and stent. Amongst them, 388 were in a bail-out situation (73.4 per cent). Results showed a significant reduction in the principal criterion (death, myocardial infarction, revascularization procedures) occurrence at 30 days (60.3 per cent; p < 0.001) and at 6 months (23.7 per cent; p = 0.043) and good safety. The greatest reduction was observed in the bail-out situation. Its efficacy must be confirmed by specific studies including health economy data in order to define the place of such an association amongst future therapies.
Pinton
P
P
Unité Thérapeutique Cardio-vasculaire, Lilly-France, Saint-Cloud, France.
D000077284:Abciximab; D000208:Acute Disease; D017130:Angioplasty; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D015607:Stents
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab